Navigation Links
Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
Date:4/29/2008

e dated April 23, 2008 for

more information regarding the EASL presentations.)

-- The lead clinical candidate from the nucleotide prodrug program,

IDX184, is on track for an investigational new drug (IND)

application submission in the first half of 2008. Based on the

preclinical pharmacology and toxicology profile of IDX184

demonstrated to date, the company anticipates that the first-in-

man clinical trial should be initiated in the second half of

2008.

-- Idenix also reported positive preclinical data from its HCV

protease inhibitor program, with internally discovered compounds

exhibiting potency in the HCV replicon system and good

pharmacokinetic profiles in several animal species.

"We have made significant progress in the last six months in the discovery and development of our HCV and HIV programs," said Jean-Pierre Sommadossi, Ph.D., chairman and chief executive officer of Idenix. "We are very pleased with the initial antiviral activity and safety data generated in the IDX899 clinical development program. Based on the profile of IDX899 exhibited to date, we believe that IDX899 could play an important role in the treatment of patients with HIV."

Sommadossi continued, "Our expertise and focus on antiviral discovery and development enables us to rapidly advance our programs through IND-enabling preclinical studies, proof-of-concept testing and into phase II clinical studies. With a comprehensive HCV discovery program in each of the major classes of direct-acting HCV antivirals, we are uniquely positioned to be one of the first companies to develop our own specifically targeted antiviral therapy for HCV (STAT-C)."

For the first quarter ended March 31, 2008, Idenix reported total revenues of $2.0 million, compared with total revenues of $24.8 million in the first quarter of 2007. Th
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
2. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
3. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
4. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
5. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
6. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
7. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
8. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
9. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
10. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
11. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... TAMPA, Fla. , July, 29  2014 ... it has hired John Bournas as ... who announced plans to leave the Society last ... with extensive competencies in the healthcare association industry ... to the Society a clear vision for the ...
(Date:7/29/2014)... LAUDERDALE, Fla. , July 29, 2014 /PRNewswire-iReach/ ... medical service provider, has launched its Medical ... Program.  These services are tailored to the ... excellent standards prompted industry operators to propose that ... MHG Medical,s new program is intended to ...
(Date:7/29/2014)... 29, 2014 According to a ... Trauma Fixation Devices Market - Global Forecast, Market Share, ... global orthopedic trauma fixation devices market is estimated at ... grow at a CAGR of 7.2% from 2014 to ... billion in 2020. Browse the Orthopedic Trauma ...
Breaking Medicine Technology:ISPE Hires Healthcare Association Exec as CEO 2ISPE Hires Healthcare Association Exec as CEO 3MHG Medical Management Services Aims to Change Cruise Industry Standard With New Equipment Maintenance Program 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 3Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 4
... 2007 /PRNewswire-USNewswire/ -- The,following statement may be attributed ... Medical Research (CAMR): , "In the face of ... the stroke of his veto pen deliberately to ... well as endanger,the future health and well being ...
... - Elixir,Pharmaceuticals, Inc., announced today the publication ... (mitiglinide calcium,hydrate) monotherapy, or combination therapy with ... meals. The data were,published in the Abstract ... Scientific Sessions in Chicago, Illinois.,Glufast is an ...
Cached Medicine Technology:President Bush Ignores America's Plea for Support of Stem Cell,Research 2Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 2Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 3Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 4Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 5
(Date:7/29/2014)... the nation,s largest interdisciplinary organization devoted to ... Bowers, PhD, RN, FAAN, of the University of Wisconsin-Madison ... Minority Issues in Gerontology Outstanding Mentorship Award. , This ... has exemplified outstanding commitment and dedication to mentoring minority ... presentation will take place at GSA,s 67th Annual Scientific ...
(Date:7/29/2014)... the nation,s largest interdisciplinary organization devoted to the ... PhD, of Cornell University as the 2014 recipient of ... in Behavioral and Social Gerontology. , This distinguished honor, ... and social gerontology. Individuals who have received their doctorate ... is given by GSA in conjunction with the Margret ...
(Date:7/29/2014)... The report “Filling Equipment Market by Industry (Food, ... Weight), Process (Manual, Semi-Automatic, Automatic), Product (Solid, Semi-Solid, ... to 2019”, defines the filling equipment market and ... segments with analyses and projections of the market ... of value. It also identifies the driving and ...
(Date:7/29/2014)... ENCINITAS, Calif. (PRWEB) July 29, 2014 ... prescription drug abuse directly at the source? That’s the ... , an innovative prescription drug abuse risk program developed ... from hundreds of applicants worldwide to be part of ... September 10-12 in San Francisco, CA. The Hive is ...
(Date:7/29/2014)... INDIANAPOLIS -- With the increasing use of electronic ... a growing demand for a computerized version of ... United States. In a new study, researchers from ... Regenstrief Institute report that substantial work lies ahead ... Future,s guidelines into computerized prompts for physicians, but ...
Breaking Medicine News(10 mins):Health News:Bowers to receive GSA's 2014 Minority Mentorship Award 2Health News:Löckenhoff earns GSA's 2014 Baltes Foundation Award 2Health News:Filling Equipment Market worth $8 Billion by 2019 - Report by MarketsandMarkets 2Health News:Filling Equipment Market worth $8 Billion by 2019 - Report by MarketsandMarkets 3Health News:Filling Equipment Market worth $8 Billion by 2019 - Report by MarketsandMarkets 4Health News:SafeUseNow Selected to Showcase at TEDMED Hive 2014 2Health News:SafeUseNow Selected to Showcase at TEDMED Hive 2014 3Health News:Study: Pediatric preventive care guidelines need retooling for computerized format 2Health News:Study: Pediatric preventive care guidelines need retooling for computerized format 3
... chronically exposed to family turmoil, violence, noise, poor housing ... strain// than other young people. ,However, when ... these negative physiological changes, reports a new study from ... that the cardiovascular systems of youths who are exposed ...
... cancer is so much more prevalent in men than women: ... in men than women plays a role in the development ... new types of treatment with the disease. ,In ... Chawnshang Chang, Ph.D., of the University of Rochester Medical Center ...
... stent therapy and bypass surgery for coronary artery disease ... event within 30 days after the procedures// , according ... similar outcomes three years after treatment. Patients with coronary ... bypass surgery to reroute the arteries' blood flow or ...
... the carotid artery by dental x-rays is not enough evidence ... a review published in the Journal of the American Dental ... leading causes of death and disability among adults in the ... and nutrients to the brain bursts or becomes clogged by ...
... head and neck cancer that targets multiple peptides (parts ... tumors. ,The researchers created the vaccine ... is mutated in most cancers and associated with poor ... also expresses unaltered, or "wild-type," p53 peptides in tumors. ...
... a dermatologist has a higher survival rate than by a ... to detect// the tumor in its early stages which can ... ,Individuals whose melanoma is diagnosed by a dermatologist may be ... years than those with melanoma diagnosed by a non-dermatologist, according ...
Cached Medicine News:Health News:Adolescents Exposed to Family Turmoil and Violence Face Stress-related Problems 2Health News:Scientists Find Clue for the Prevalence of Bladder Cancer More in Men 2Health News:Scientists Find Clue for the Prevalence of Bladder Cancer More in Men 3Health News:Scientists Find Clue for the Prevalence of Bladder Cancer More in Men 4Health News:Bypass Surgery, Drug-eluting Stents Possess Similar Risk and Outcome 2Health News:Dental X-rays of Carotid Artery Cannot Estimate Stroke Risk 2Health News:Head and Neck Cancer Vaccine Targets Proteins to Create Immune Response 2Health News:Chances of Survival for Melanoma is High When Detected by Dermatologists 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: